PA
ULCC icon

PharVision Advisers’s Frontier Group Holdings ULCC Stock Holding History

PharVision Advisers’s Portfolio ULCC Stock Details ULCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-96,681
Closed -$455K – 621
2025
Q4 		$455K Buy
+96,681
New +$428K 0.23% 66

Other funds holding ULCC

IP
Indigo Partners Phoenix, Arizona $267M AUM 9% 1-Year Est. Return
WCM
Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return
USGIU
U.S. Global Investors (USGI) San Antonio, Texas $858M AUM 47.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AA
Ancient Art Austin, Texas $459M AUM 52.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

PharVision Advisers's ULCC Position: Q1 2026 in Review

PharVision Advisers sold out of Frontier Group Holdings (ULCC) in Q1 2026, closing a stake of 96,681 shares — an estimated $455K sold.

PharVision Advisers first reported a position in ULCC in Q4 2025 and held it in 1 quarter. The position peaked at $455K in Q4 2025. 161 funds tracked by Wall St. Rank hold ULCC as of Q1 2026.

  • PharVision Advisers reported no remaining Frontier Group Holdings position as of Q1 2026 after selling out during the quarter.
  • PharVision Advisers sold 96,681 Frontier Group Holdings shares in Q1 2026, an estimated $455K.
  • PharVision Advisers first reported a position in Frontier Group Holdings in Q4 2025 and held it in 1 quarter.
  • PharVision Advisers's Frontier Group Holdings position peaked at $455K in Q4 2025.
  • 161 funds tracked by Wall St. Rank held Frontier Group Holdings as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.